Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 11, 2026HematologyOpen Access

Switching patients with PNH from pegcetacoplan to iptacopan: a case series

View Full Paper
Ask AI
Bookmark
Share

Authors

MOMark OrlandCleveland ClinicCGCarmelo GurnariUniversity of Rome Tor VergataSSSrinivasa Reddy SanikommuLevine Cancer Institute

Discussion

Loading...

Member takes

Implication

Case series demonstrates successful transition to iptacopan in PNH patients, suggesting safety and efficacy.

Key Points

  • To evaluate the feasibility and safety of transitioning patients with PNH from pegcetacoplan to iptacopan.
  • Observed three patients with PNH
  • Transitioned patients from pegcetacoplan to iptacopan
  • Monitored laboratory evidence of BTH, EVH, and intravascular hemolysis
  • No patients exhibited laboratory evidence of BTH after the switch
  • No evidence of EVH was observed
  • There was no intravascular hemolysis reported post-transition

Cite This Study

Orland et al. (2026) studied this question.

synapsesocial.com/papers/698c1c73267fb587c655ee75https://doi.org/10.1080/16078454.2026.2618403
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria2024 · 150 citations
  2. 2Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study2023 · 26 citations
  3. 3Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis2024 · 23 citations
  4. 4Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment2025 · 9 citations
  5. 5Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria2023 · 62 citations